ORPHA:1656
Dermatitis herpetiformis
Also known as: Duhring-Brocq disease
Publications
7,126
95.5th percentile
Trials
2
Interventional, condition-specific
Researchers
948
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A chronic autoimmune subepidermal bullous disease characterized by grouped pruritic lesions such as papules, urticarial plaques, erythema, and herpetiform vesiculae, with a predominantly symmetrical distribution on extensor surfaces of the elbows (90%), knees (30%), shoulders, buttocks, sacral region, and face of children and adults. Erosions, excoriations and hyperpigmentation usually follow. It may also appear as a consequence of gluten intolerance.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015614
- MeSH:D003874
- UMLS:C0011608
- NCIT:C26742
Additional Mondo synonyms (3)
Duhring's disease · Durhing-Brocq disease · dermatitis herpetiformis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7,126 matched papers (1,998 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7,126
7,126 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7,126 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,998 in the last 10 years · high confidence · 95.5th percentile (publications denominator)
Phrase hits: 7,126 · MeSH hits: 0
Who's working on it?
948
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Salmi T10 papers · 2026
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Papers in Europe PMC - 02Kaukinen K9 papers · 2026
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Papers in Europe PMC - 03Hervonen K8 papers · 2026
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Papers in Europe PMC - 04Huhtala H7 papers · 2026
Faculty of Social Sciences, Tampere University, Tampere, Finland.
Papers in Europe PMC - 05Pasternack C6 papers · 2026
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Papers in Europe PMC - 06Reunala T5 papers · 2026
Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Papers in Europe PMC - 07
- 08Drenovska K4 papers · 2026
Department of Dermatology and Venereology, Medical University - Sofia, Sofia , Bulgaria.
Papers in Europe PMC - 09Lindfors K4 papers · 2026
Celiac Disease Research Center, Tampere University, Tampere, Finland.
Papers in Europe PMC - 10Caproni M3 papers · 2026
Deparment of Health Sciences, Section of Dermatology, Rare Diseases Unit, European Reference Network-Skin Member, University of Florence, Florence , Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 1,584 trials are registered for dermatitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
2 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 82.4th percentile).
high confidence · 82.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: dermatitis
1,584
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07713186·NOT YET RECRUITING·Azithromycin in Atopic Dermatitis
Conditions: Atopic Dermatitis·Matched via name phrase
- NCT07641686·RECRUITING·A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients
Conditions: Hair Transplantation · Seborrheic Dermatitis · Scalp Care·Matched via name phrase
- NCT07103174·NOT YET RECRUITING·A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
Conditions: Atopic Dermatitis (AD)·Matched via name phrase
- NCT06390696·RECRUITING·Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis
Conditions: Atopic Dermatitis · Nature, Human · Microbial Colonization · Immune System and Related Disorders·Matched via name phrase
- NCT07056569·RECRUITING·Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters
Conditions: Dermatitis, Contact · Dermatitis · Dermatitis, Chronic · Dermatitis, Eczematous·Matched via name phrase
- NCT07683806·NOT YET RECRUITING·Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Conditions: Seborrheic Dermatitis·Matched via name phrase
- NCT06487000·NOT YET RECRUITING·Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
Conditions: Atopic Dermatitis·Matched via name phrase
- NCT07193589·RECRUITING·A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
Conditions: Atopic Dermatitis·Matched via name phrase
- NCT06808477·RECRUITING·A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Conditions: Atopic Dermatitis·Matched via name phrase
- NCT07380230·NOT YET RECRUITING·Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients
Conditions: Acute Radiation Dermatitis · Traditional Chinese Medicine (TCM) · Breast Cancer·Matched via name phrase
- NCT05858619·RECRUITING·Molecular Signatures of Cutaneous Dupilumab Response
Conditions: Atopic Dermatitis·Matched via name phrase
- NCT07524439·RECRUITING·Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent
Conditions: Fecal Incontinence · Urinary Incontinence · Diaper Rash · Irritant Contact Dermatitis Caused by Faeces·Matched via name phrase
- NCT07355075·RECRUITING·A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Conditions: Eczema Atopic Dermatitis · Eczema · Atopic Dermatitis·Matched via name phrase
- NCT06982352·RECRUITING·Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Conditions: Atopic Dermatitis (AD) · Psoriasis (PsO)·Matched via name phrase
- NCT06934252·RECRUITING·Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
Conditions: Moderate-to-severe Atopic Dermatitis·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05597904·RECRUITING·Background of Different Phenotypes of Coeliac Disease
Conditions: Celiac Disease · Dermatitis Herpetiformis·Matched via name phrase
- NCT05998291·ENROLLING BY INVITATION·Dermatitis Herpetiformis Refractory to Gluten Free Diet
Conditions: Dermatitis Herpetiformis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Dermatitis herpetiformis" OR "Duhring-Brocq disease" OR "Duhring's disease" OR "Durhing-Brocq disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Dermatitis herpetiformis" OR "Duhring-Brocq disease" OR "Duhring's disease" OR "Durhing-Brocq disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"dermatitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T17:53:22.503Z
